期刊文献+

Challenges related to clinical decision-making in hepatocellular carcinoma recurrence post-liver transplantation: Is there a hope?

下载PDF
导出
摘要 Hepatocellular carcinoma(HCC)is a common liver malignancy and represents a serious cause of cancer-related mortality and morbidity.One of the favourable curative surgical therapeutic options for HCC is liver transplantation(LT)in selected patients fulfilling the known standard Milan/University of California San Francisco criteria which have shown better outcomes and longer-term survival.Despite careful adherence to the strict HCC selection criteria for LT in different transplant centres,the recurrence rate still occurs which could negatively affect HCC patients’survival.Hence HCC recurrence post-LT could predict patients’survival and prognosis,depending on the exact timing of recurrence after LT(early or late),and whether intra/extrahepatic HCC recurrence.Several factors may aid in such a complication,particularly tumour-related criteria including larger sizes,higher grades or poor tumour differentiation,microvascular invasion,and elevated serum alpha-fetoprotein.Therefore,managing such cases is challenging,different therapeutic options have been proposed,including curative surgical and ablative treatments that have shown better outcomes,compared to the palliative locoregional and systemic therapies,which may be helpful in those with unresectable tumour burden.To handle all these issues in our review.
出处 《World Journal of Transplantation》 2024年第3期70-79,共10页 世界移植杂志
  • 相关文献

参考文献5

二级参考文献24

  • 1Abhijeet Waghray,Bengi Balci,Galal El‐Gazzaz,Richard Kim,Robert Pelley,KV Narayanan Menon,Bassam Estfan,Carlos Romero‐Marrero,Federico Aucejo.Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Clin Transplant . 2013 (4)
  • 2Carlo Sposito,Luigi Mariani,Alessandro Germini,Maria Flores Reyes,Marco Bongini,Glenda Grossi,Sherrie Bhoori,Vincenzo Mazzaferro.Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study<!-- Doctopic: TAS -->[J]. Journal of Hepatology . 2013 (1)
  • 3Young‐Nam Roh,Choon Hyuck David Kwon,Sanghyun Song,Milljae Shin,Jong Man Kim,Sungjoo Kim,Jae‐Won Joh,Suk‐Koo Lee.The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation[J]. Clin Transplant . 2014 (1)
  • 4Claudio Zavaglia,Aldo Airoldi,Andrea Mancuso,Marcello Vangeli,Raffaella Viganò,Gabriella Cordone,Maria Gentiluomo,Luca Saverio Belli.Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature[J]. European Journal of Gastroenterology & Hepatology . 2013 (2)
  • 5Franco Trevisani,Francesca Garuti,Alessandro Cucchetti,Barbara Lenzi,Mauro Bernardi.De novo hepatocellular carcinoma of liver allograft: A neglected issue[J]. Cancer Letters . 2014
  • 6Alsina, Angel E,Makris, Alexia,Nenos, Vasilios,Sucre, Eduardo,Arrobas, Jade,Franco, Edson,Kemmer, Nyingi.Can Sorafenib Increase Survival for Recurrent Hepatocellular Carcinoma after Liver Transplantation? A Pilot Study[J]. The American Surgeon . 2014 (7)
  • 7P. De Simone,L. Crocetti,D. Pezzati,I. Bargellini,D. Ghinolfi,P. Carrai,G. Leonardi,C. Della Pina,D. Cioni,L. Pollina,D. Campani,C. Bartolozzi,R. Lencioni,F. Filipponi.Efficacy and Safety of Combination Therapy With Everolimus and Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation[J]. Transplantation Proceedings . 2014 (1)
  • 8Giovanni Perricone,Andrea Mancuso,Luca S. Belli,Chiara Mazzarelli,Claudio Zavaglia.Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?[J]. European Journal of Gastroenterology & Hepatology . 2014 (5)
  • 9Jan Pfeiffenberger,Ronald Koschny,Katrin Hoffmann,Arianeb Mehrabi,Anne Schmitz,Boris Radeleff,Wolfgang Stremmel,Peter Schemmer,Tom M. Ganten.Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation[J]. Langenbeck’s Archives of Surgery . 2013 (8)
  • 10Christian Toso,Gilles Mentha,Pietro Majno.Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence<!-- Doctopic: Editorial -->[J]. Journal of Hepatology . 2013 (1)

共引文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部